IRLAB publishes recorded speech and company presentation prior to digital AGM

May 5, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that a video recording for the digital annual general meeting (AGM) 2021 is available on the company’s website, www.irlab.se. The video recording includes a speech from the Chair of the board, presentation of the newly proposed board member and company presentation. The video is intended to provide information to shareholders as a basis for the digital postal voting, which is ongoing until 5 May 2021.

[mfn_before_post]

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that a video recording for the digital annual general meeting (AGM) 2021 is available on the company's website, www.irlab.se. The video recording includes a speech from the Chair of the board, presentation of the newly proposed board member and company presentation. The video is intended to provide information to shareholders as a basis for the digital postal voting, which is ongoing until 5 May 2021.

Due to the continued spread of Covid-19 and to ensure the safety of our shareholders, the annual general meeting will this year be held without physical presence, as previously announced.

Participation at the annual general meeting will instead occur by using a digital postal voting form, available on www.irlab.se in the menu ‘Corporate Governance’ or through the following link: www.bit.ly/IRLAB-AGM21.

For more information

Nicholas Waters, CEO                
Phone: +46 730 75 77 01                
E-mail: nicholas.waters@irlab.se

Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se

About IRLAB

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se.

[mfn_after_post]

Documents & Links